Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Invivyd, Inc. - Common Stock
(NQ:
IVVD
)
1.400
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Feb 19, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
73,650
Open
1.400
Bid (Size)
1.350 (2)
Ask (Size)
1.360 (9)
Prev. Close
1.400
Today's Range
1.400 - 1.400
52wk Range
0.3546 - 4.740
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
February 11, 2025
Via
Benzinga
Invivyd to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025
February 10, 2025
From
Invivyd
Via
GlobeNewswire
Performance
YTD
+191.67%
+191.67%
1 Month
+243.56%
+243.56%
3 Month
+82.27%
+82.27%
6 Month
+59.45%
+59.45%
1 Year
-65.85%
-65.85%
More News
Read More
These 5 Health Care Stocks Saw The Sharpest Retail Interest Jump Last Week
February 10, 2025
Via
Stocktwits
Exposures
Product Safety
Which stocks are experiencing notable movement on Friday?
February 07, 2025
Via
Chartmill
(IVVD) - Analyzing Invivyd's Short Interest
February 05, 2025
Via
Benzinga
On Thursday, there are stocks with unusual volume. Let's take a look.
February 06, 2025
Via
Chartmill
12 Health Care Stocks Moving In Thursday's Pre-Market Session
February 06, 2025
Via
Benzinga
Here are the top movers in Wednesday's session.
February 05, 2025
Via
Chartmill
Invivyd Announces Partnership with Pro Football Coach Jim Harbaugh to Elevate Awareness and Ongoing Impact of COVID-19: Common, Not A Cold
February 05, 2025
From
Invivyd
Via
GlobeNewswire
Tuesday's session: most active stocks
February 04, 2025
Via
Chartmill
Unusual volume stocks in Tuesday's session
February 04, 2025
Via
Chartmill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
February 04, 2025
Via
Benzinga
Why Palantir Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket
February 04, 2025
Via
Benzinga
Top movers in Monday's session
February 03, 2025
Via
Chartmill
Discover the most active stocks in Monday's session.
February 03, 2025
Via
Chartmill
Keep an eye on the top gainers and losers in Monday's session.
February 03, 2025
Via
Chartmill
Traders are paying attention to the gapping stocks in Monday's session.
February 03, 2025
Via
Chartmill
Invivyd Touts Encouraging Data From COVID-19 Antibody Trial, Stock Jumps
February 03, 2025
Via
Benzinga
Exposures
COVID-19
Stay updated with the stocks that are on the move in today's pre-market session.
February 03, 2025
Via
Chartmill
12 Health Care Stocks Moving In Monday's Pre-Market Session
February 03, 2025
Via
Benzinga
Invivyd Announces Positive Phase 1/2 Clinical Data for VYD2311, a Monoclonal Antibody Designed to be a Superior Alternative to COVID-19 Vaccination for the Broad Population
February 03, 2025
From
Invivyd
Via
GlobeNewswire
Invivyd Announces Preliminary Fourth Quarter 2024 Financial Results, Strong Revenue Growth, and Reiterates Goal of Near-Term Profitability
February 03, 2025
From
Invivyd
Via
GlobeNewswire
Which stocks are moving after the closing bell on Friday?
January 31, 2025
Via
Chartmill
Curious about the stocks that are showing activity after the closing bell on Monday?
January 27, 2025
Via
Chartmill
Invivyd Provides Another Positive SARS-CoV-2 Variant Data Analysis to Satisfy U.S. FDA’s Gating Request for Completing Its Review of EUA Request for PEMGARDA™ (pemivibart) for the Treatment of Mild-to-Moderate COVID-19 in Certain Immunocompromised
January 27, 2025
From
Invivyd
Via
GlobeNewswire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.